Radiology and Oncology最新文献

{"title":"Impaired booster-induced SARS-CoV-2 antibody responses in rituximab-treated B-cell lymphoma patients despite peripheral B-Cell Recovery.","authors":"Tomaz Jurca, Lucka Boltezar, Miha Orazem, Kristina Fujs Komlos, Katka Pohar, Sara Jevnikar, Mario Poljak, Denis Mlakar Mastnak, Nada Rotovnik Kozjek, Bor Vratanar, Janja Ocvirk, Alojz Ihan","doi":"10.2478/raon-2026-0014","DOIUrl":"10.2478/raon-2026-0014","url":null,"abstract":"<p><strong>Background: </strong>Rituximab-treated patients with B-cell lymphoma exhibit profound B-cell depletion and impaired vaccine-induced antibody responses. However, it remains uncertain whether recovery of peripheral B-cell counts after rituximab is sufficient to restore effective humoral immunity following booster vaccination.</p><p><strong>Patients and methods: </strong>In this prospective, single-center observational study at the Institute of Oncology Ljubljana, adult B-cell lymphoma patients treated with or previously exposed to rituximab received the Comirnaty® mRNA COVID-19 vaccine. Antibody responses to the SARS-CoV-2 spike and nucleoprotein were measured at baseline, 14 days after the second dose, and at 3, 6, 9, and 12 months. A third dose was administered at 6 months. T-cell responses (IFN-γ release) were assessed in patients before and after the primary series and booster dose. Lymphocyte subsets were analysed pre-vaccination. Adverse events and nutritional status were monitored.</p><p><strong>Results: </strong>Patients undergoing anti-CD20 therapy showed absent antibody responses. Longer intervals since rituximab correlated with peripheral B-cell repopulation. However, even after reaching normal B-cell counts, patients' antibody responses after revaccination remained significantly lower than in controls.</p><p><strong>Conclusions: </strong>Rituximab is associated with impaired vaccine-induced antibody responses. Despite recovery of peripheral B-cell counts, patients with B-cell lymphoma show reduced humoral responses compared with healthy individuals following booster COVID-19 vaccination.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"60 1","pages":"76-85"},"PeriodicalIF":2.2,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147514421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for malignant spinal cord compression - prognostic factors for better functional outcome.","authors":"Jasna But-Hadzic, Blaz Groselj, Dirk Rades, Barbara Segedin","doi":"10.2478/raon-2026-0013","DOIUrl":"10.2478/raon-2026-0013","url":null,"abstract":"<p><strong>Background: </strong>Malignant spinal cord compression (MSCC) is one of the most devastating complications in cancer patients. This retrospective single-center analysis was aimed to identify prognostic factors for better functional outcome after radiotherapy for MSCC.</p><p><strong>Patients and methods: </strong>Consecutive patients with MSCC treated with upfront radiotherapy between January 2017 and December 2022 were included in this analysis. Data on patient, tumor and treatment characteristics, functional status before and after treatment and diagnostic work-up were collected from the hospital digital database. The treatment was considered effective if performance status (PS) was maintained in PS 1-2 patients or PS improved in PS 3-4 patients.</p><p><strong>Results: </strong>295 patients were treated for MSCC. The most common primary tumor type was lung cancer (29.3%), followed by prostate (18%) and breast cancer (12%). The treatment was effective in 44.7% of patients. Patients who survived more than 1 month after radiotherapy were more likely to experience functional improvement than patients who died within the first month (60.5% <i>vs</i>. 16.5%, p < 0.001). In the multivariate analysis PS 1-2, myeloma/lymphoma, MRI at the time of MSCC and no motor deficits <i>vs</i>. paralysis were associated with better functional outcome.</p><p><strong>Conclusions: </strong>The prognosis of patients with MSCC remains poor. Better stratification of patients to assess possible benefit of radiotherapy for MSCC is warranted.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"60 1","pages":"132-140"},"PeriodicalIF":2.2,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147514412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of malignant bowel obstruction in patients with advanced cancer at the end of life.","authors":"Nena Golob, Rok Petric, Maja Ebert Moltara","doi":"10.2478/raon-2026-0010","DOIUrl":"https://doi.org/10.2478/raon-2026-0010","url":null,"abstract":"<p><strong>Background: </strong>Malignant bowel obstruction in patients with advanced cancer at the end of life is common. Patients may have substantial symptoms (pain, nausea and vomiting) and experience aggressive care at the end of life. Due to the lack of robust evidence, the care algorithm of treatment for patients at the end of life is not standardized. Patient's prognosis, clinical condition and patient's preferences related to goals of care discussion must be considered when opting between comfort-focused care (conservative/pharmacological treatment), palliative (nonsurgical) procedures and palliative surgery.</p><p><strong>Patients and methods: </strong>A focused literature search was conducted in PubMed/Medline to identify recommendations on the management of malignant bowel obstruction in patients with advanced cancer at the end of life. The search focused on symptom management using Medical Subject Headings (MeSH) terms related to intestinal obstruction in patients with advanced cancer at the end of life.</p><p><strong>Results: </strong>Using the MeSH terms related search in PubMed/Medline, 9,532 articles were initially identified. After applying filters, 535 articles were selected for further review. Additional sources included reference lists and grey literature. In total, 83 references were used to support the management recommendations/suggestions in this article.</p><p><strong>Conclusions: </strong>It is essential to engage patients and families in goals of care discussions to promote understanding of the palliative intent of different malignant bowel obstruction interventions. Research is needed to assist clinicians in decision making to provide patients at the end of life with appropriate care. Criteria for the selection of candidates for palliative surgery are needed to avoid significant complications and overly aggressive treatment at the end of life when the focus is maintaining and enhancing the quality of life of patients.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric comparison of organs at risk in ultra-hypofractionated versus hypofractionated postoperative radiotherapy for early breast cancer: single center clinical study.","authors":"Gordana Petkovska, Ivica Ratosa, Valentina Bojovska Trajanovska, Marina Iljovska, Albina Pupakovski Creslovnik, Emilija Lazareva","doi":"10.2478/raon-2026-0008","DOIUrl":"10.2478/raon-2026-0008","url":null,"abstract":"<p><strong>Background: </strong>Growing evidence of safety and feasibility has prompted a shift toward ultra-hypofractionated (UHF) schedules in postoperative radiotherapy in early breast cancer.</p><p><strong>Patients and methods: </strong>Eighty patients over 50 years of age with early breast cancer (T1-2 and N0-1) who underwent postoperative, 3D conformal, free-breathing whole breast radiotherapy were included. The prospective arm consisted of 40 patients treated with UHF (26 Gy/5 fractions/one week) from 2023-2024, whereas the control arm was retrospective and represented by data from 40 patients treated with hypofractionated radiotherapy (HF) (40.5-42.2Gy/15-16 fractions/3 weeks) between 2015 and 2020. Dosimetric parameters for organs at risk (OARs) (heart and ipsilateral lung) were derived from the dose-volume histograms. Statistical evaluation was done with paired sample t-test and Mann-Whitney U test.</p><p><strong>Results: </strong>Dosimetric analysis revealed that patients treated with UHF schedule received significantly lower equivalent doses in 2 Gy fractions (EQD₂Gy) to OARs compared with those treated with the HF schedule. The mean ipsilateral lung EQD₂Gy dose was significantly lower in the UHF group (3.94 ± 2.1 Gy) than in the HF group (6.24 ± 2.4 Gy; <i>p</i> < 0.01). Among patients with left-sided breast cancer, the mean heart EQD₂Gy dose was also significantly reduced in the UHF group (1.34 ± 0.5 Gy) compared with the HF group (3.02 ± 1.4 Gy; <i>p</i> < 0.01).</p><p><strong>Conclusions: </strong>These findings indicate a consistent dosimetric advantage of the UHF schedule, particularly in reducing radiation exposure to the heart and ipsilateral lung. These results support the dosimetric safety and feasibility of UHF schedules in early breast cancer treatment.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"124-131"},"PeriodicalIF":2.2,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interactions between hematological biomarkers of virus infection and immune cells in mediating distant metastasis in nasopharyngeal carcinoma: insights into prognosis and induction chemotherapy administration.","authors":"Shuqi Li, Biyun Chen, Di Cao, Chao Luo, Zhiying Liang, Ian Kou, Ge Ren, Wenjie Huang, Guangying Ruan, Lizhi Liu, Haojiang Li, Siyu Zhu, Ai Fei","doi":"10.2478/raon-2026-0005","DOIUrl":"10.2478/raon-2026-0005","url":null,"abstract":"<p><strong>Background: </strong>Considering the increased metastatic risk in hepatitis B surface antigen (HBsAg)-positive patients with nasopharyngeal carcinoma (NPC), we aimed to investigate the interactions among HBsAg, tumor burden indicators, and immune function in the accurate stratification of prognosis and treatment for this specific cohort.</p><p><strong>Patients and methods: </strong>We retrospectively analysed 1650 pathologically-confirmed patients with NPC from two centers and performed interaction and mediation analyses among HBsAg, plasma Epstein-Barr virus (EBV) DNA load, and absolute lymphocyte count (ALC), concerning distant metastasis. A 1:1 random matched-paired analysis was performed to evaluate survival according to risk and treatment stratification. Treatment-related adverse events were also compared.</p><p><strong>Results: </strong>Overall, 17.3% (285/1650) of patients tested positive for HBsAg. Significant interactions occurred between HBsAg and low ALC (≤ 1.9×10⁹/L) (HL), as well as between HBsAg and high plasma EBV DNA load (> 4000 copies/mL) (HE), both independently predicting poor distant metastasis-free survival (DMFS). The influence of T and N staging on tumor metastasis was mediated by HL (+) and HE (+), respectively. Among patients with stage III-IVa NPC, interaction associations presented with a worse 5-year DMFS and higher rates of severe neutropenia and leukopenia among those treated with additional induction chemotherapy (IC) than among those treated with radiochemotherapy alone.</p><p><strong>Conclusions: </strong>Interactions exist between HBsAg positivity and high EBV/low ALC, mediating the effects of tumor staging and distant metastasis. The collective influence of viral infection, tumor burden, and reduced immune cells leads to worse DMFS in patients with HBsAg-positive NPC, requiring a tailored treatment beyond IC.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"86-96"},"PeriodicalIF":2.2,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histopathologic growth patterns as prognostic factor for survival in patients with colorectal liver metastases.","authors":"Sarkis Drejian, Mehdi Sadat Akhavi, Krzyztof Grzyb, Airazat Kazaryan, Åsmund Avdam Fretland, Bjørn Edwin, Davit Aghayan","doi":"10.2478/raon-2026-0002","DOIUrl":"10.2478/raon-2026-0002","url":null,"abstract":"<p><strong>Background: </strong>Histopathologic growth patterns (HGPs) of colorectal liver metastases (CRLM) have emerged as potential prognostic biomarkers, though their clinical significance remains under investigation. The objective is to evaluate the prognostic value of HGPs on recurrence-free survival (RFS) and overall survival (OS) in patients undergoing liver resection for CRLM.</p><p><strong>Patients and methods: </strong>This was a retrospective analysis of the OSLO-COMET randomized controlled trial, where 280 patients underwent laparoscopic or open parenchyma-sparing liver resection for CRLM between February 2012 and February 2016. Patients eligible for long-term analysis and with available histological material were included. HGPs were categorized as desmoplastic, pushing, replacement, or mixed, according to international consensus guidelines. Kaplan-Meier and Cox proportional hazards models were used to evaluate associations between HGPs and survival.</p><p><strong>Results: </strong>A total of 239 patients were included. Desmoplastic HGP was present in 43.5% of patients and associated with significantly better outcomes. Median RFS was 31 months for desmoplastic versus 9, 10, and 11 months for replacement, pushing, and mixed groups, respectively (p = 0.002). Five-year OS was 62% for desmoplastic, 59% for replacement, 55% for mixed, and 39% for pushing HGP (p = 0.036). In multivariable analysis, HGP, lymph node status, and extrahepatic disease were independent predictors of RFS. Age, tumor size, ECOG score, and extrahepatic metastasis significantly impacted OS.</p><p><strong>Conclusions: </strong>Replacement, pushing and mixed HGPs were associated with poor RFS, although replacement and mixed patterns showed better OS after treatment of recurrences. Desmoplastic HGP was independently associated with better RFS and OS following resection for CRLM.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"114-123"},"PeriodicalIF":2.2,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-channel ultrasonic images empowered deep learning: significantly improving prediction of occult central lymph node metastases in solitary papillary thyroid microcarcinoma.","authors":"Meihua Li, Chao Jia, Gang Li, Qiusheng Shi, Long Liu","doi":"10.2478/raon-2026-0006","DOIUrl":"10.2478/raon-2026-0006","url":null,"abstract":"<p><strong>Background: </strong>Central lymph node metastasis (CLNM) significantly elevates the risk of postoperative recurrence and contributes to ongoing debates regarding the necessity of prophylactic dissection in clinically node-negative papillary thyroid microcarcinoma (PTMC). Therefore, accurate preoperative prediction of occult CLNM is crucial for tailoring individualized treatment strategies.</p><p><strong>Patients and methods: </strong>This retrospective study included 461 patients with PTMC from two hospitals who underwent preoperative ultrasound. A dual-channel deep learning (DL) model was developed by combining longitudinal and transverse ultrasound images. The model's performance was compared with single-direction DL models and a clinical model using machine learning classifiers. Performance was evaluated using the area under the receiver operating characteristic curve (AUC) and calibration curves.</p><p><strong>Results: </strong>The dual-channel DL model outperformed the single-direction models, with AUC values of 0.765 in the training set and 0.726 in the external test set. The combined model, which integrated DL features and clinical indicators, achieved the highest AUC of 0.900 in the training set and 0.873 in the external test set, surpassing both the deep learning model using fused DL model (DL_F) and clinical models.</p><p><strong>Conclusions: </strong>The dual-channel DL model demonstrated superior performance in predicting occult CLNM in PTMC patients. When combined with clinical features, it offers a robust tool for personalized risk stratification and treatment decision-making, providing a non-invasive method for predicting occult CLNM and supporting individualized treatment strategies.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"49-58"},"PeriodicalIF":2.2,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging-based prognostic factors in patients undergoing thermal ablation for colorectal liver metastases. A retrospective study on the role of sarcopenia parameters and tumor burden score.","authors":"Maximilian Moos, Lena Maria Jacobi, Fabian Stoehr, Paul Steiner, Tobias Bäuerle, Roman Kloeckner, Constantin Scholz, Hauke Lang, Lukas Müller, Felix Hahn","doi":"10.2478/raon-2026-0011","DOIUrl":"10.2478/raon-2026-0011","url":null,"abstract":"<p><strong>Background: </strong>To investigate imaging-based prognostic factors in patients who underwent thermal ablation for colorectal liver metastases (CRLM), with a focus on sarcopenia-related body composition parameters and L1-bone-density in comparison to tumor burden score (TBS).</p><p><strong>Patients and methods: </strong>A retrospective analysis was conducted on patients who received thermal ablation for CRLM at our tertiary care center between 2009 and 2023. CT-derived body composition metrics included the psoas muscle volume index (PMVI), the psoas muscle index (PMI), and L1-bone-density. PMVI was automatically extracted using the open-source deep learning tool TotalSegmentator. Comparisons between 1-year survivors and non-survivors were performed using unpaired t-tests.</p><p><strong>Results: </strong>A total of 88 patients were included, most had previously undergone hepatic resection (n = 72, 82%). Among sarcopenia-related imaging markers, PMVI showed a significant association with 1-year survival (p = 0.048), with higher PMVI values observed in survivors (mean 113.3 cm³/m³) compared to non-survivors (mean 101.3 cm³/m³). No significant differences were observed for L1-density (p = 0.925) or PMI (p = 0.137). Similarly, the TBS was not significantly associated with 1-year survival (p = 0.182).</p><p><strong>Conclusions: </strong>In our cohort of patients treated with thermal ablation for CRLM, PMVI showed significant association with 1-year survival, which was not observed for conventional tumor burden score or other sarcopenia-related imaging parameters.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"32-39"},"PeriodicalIF":2.2,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inequity in access to palliative care services worldwide and in Slovenia.","authors":"Nena Golob, Maja Ebert Moltara","doi":"10.2478/raon-2026-0009","DOIUrl":"10.2478/raon-2026-0009","url":null,"abstract":"<p><strong>Background: </strong>Palliative care aims to enhance the quality of life of patients and their families facing progressive and incurable disease by addressing physical, psychological, social, and spiritual challenges. Despite being recognized as a human right, palliative care remains out of reach for most people worldwide, with only about 14% of those who need it receiving it. Global demand for palliative care is rising due to aging populations and the increasing burden of chronic diseases. While high-income countries focus on expanding access and inclusivity to this care, low-income countries face severe shortages in prevention, diagnostics and treatment of underlying diseases, which creates an urgent need for palliative care services. Cultural differences, a lack of trained professionals, limited opioid availability, and weak policy further deepen inequities.</p><p><strong>Conclusions: </strong>Historically rooted in religious and charitable care, modern palliative care emerged with Dame Cicely Saunders' hospice movement, evolving into a medical specialty. Access varies widely - Europe has high integration in some countries but significant disparities in service distribution and opioid use. Africa, Latin America, and parts of Asia still lack widespread provision. In Slovenia, palliative care development began in the 1980s and has recently expanded to include some specialized palliative care services across the country. Despite this progress, palliative care in Slovenia remains underdeveloped due to limited coverage, regional disparities, workforce shortages, insufficient formal education, and an old and ineffective national policy. Opioid availability is slightly below the European average, and its use is declining, which raises concerns about further unmet needs.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"15-21"},"PeriodicalIF":2.2,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in Slovenian patients with skull base tumours: cross-cultural adaptation and validation of a Slovenian skull base inventory.","authors":"Domen Vozel, Jure Urbancic, Saba Battelino, Nina Bozanic Urbancic, Nejc Steiner, Tomislav Felbabic, Roman Bosnjak","doi":"10.2478/raon-2026-0007","DOIUrl":"10.2478/raon-2026-0007","url":null,"abstract":"<p><strong>Background: </strong>Skull base tumours frequently manifest as severe physical morbidity and quality of life (QoL) impairment. The disease-related QoL measurement can be performed with disease specific questionnaires, e.g. Skull base inventory (SBI).</p><p><strong>Patients and methods: </strong>The study consisted of two parts: (1) cross-cultural adaptation and psychometric testing of the Slovenian SBI (SBI-SLO) and (2) QoL assessment in skull base tumours. Two groups completed the SBI-SLO: 1.) adult patients without prior treatment of anterior, anterolateral and/or central skull base and 2.) healthy controls. Patients with skull-base tumours were further analysed for difference in SBI-SLO total score and domain scores between 1.) benign and malignant tumours and 2.) pituitary macroadenomas and other benign tumours.</p><p><strong>Results: </strong>59 patients (46% male, 54% female, median age 57.7 years) and 47 subjects from control group (49% male, 51% female, median age 42,2 years) completed SBI-SLO, which demonstrated an excellent level of internal consistency (Cronbach's alpha = 0.924) and excellent test-retest reliability (intraclass correlation coefficient [ICCA] = 0.952). The discriminant validity was confirmed (<i>p</i> = 0.000). SBI-SLO total score, emotional, other and family domain scores were lower in malignant than in benign tumours (<i>p</i> = 0.031, <i>p</i> = 0.038, <i>p</i> = 0.008, and <i>p</i> = 0.046, respectively). Macroadenoma and other benign tumours differed only in neurological domain score (p < 0.05).</p><p><strong>Conclusions: </strong>A skull base tumour, especially malignant, can exert a substantial detrimental effect on a patient's quality of life. The SBI is a key tool for assessing QoL, also available in Slovenian.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"106-113"},"PeriodicalIF":2.2,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}